Advertisement

Meta-Analysis Comparing Left Atrial Appendage Occlusion, Direct Oral Anticoagulants, and Warfarin for Nonvalvular Atrial Fibrillation

Published:October 29, 2022DOI:https://doi.org/10.1016/j.amjcard.2022.08.012
      Randomized trials have shown that direct oral anticoagulants (DOACs) are superior to warfarin in patients with nonvalvular atrial fibrillation. However, long-term use of anticoagulation carries an inherent risk of bleeding and nonadherence. Although the use of percutaneous left atrial appendage occlusion (LAAO) has become readily available, its effectiveness relative to oral anticoagulants is still unclear. The present study aimed to compare the outcomes of warfarin, DOACs, and LAAO in patients with atrial fibrillation. Medline, Embase, CENTRAL, and Web of Science were systematically searched through December 2021 for randomized controlled trials comparing warfarin, DOACs, or LAAO, reporting on all-cause mortality, stroke, and clinically relevant bleeding. A random-effects model was used to assess the safety and efficacy outcomes of these 3 treatments relative to each other in a Bayesian network meta-analysis. A total of 40 trials with 95,469 patients (LAAO: 5 trials, 3,032 patients; DOAC: 36 trials, 54,327 patients; warfarin: 37 trials, 38,110 patients) were included. LAAO was associated with significantly lower mortality than warfarin (odds ratio [OR] 0.68; 95% credible interval [CrI] 0.50 to 0.90) and DOACs (OR 0.75, 95% CrI 0.55 to 0.99). LAAO was the best-ranked treatment with respect to mortality reduction (surface under the cumulative ranking curve [SUCRA] 98.77%) and bleeding avoidance (SUCRA 72.26%). Compared with warfarin, DOACs significantly reduced mortality (OR 0.91, 95% CrI 0.85 to 0.97), stroke (OR 0.80, 95% CrI 0.63 to 0.93), and bleeding (OR 0.78, 95% CrI 0.63 to 0.95) and were ranked as the best option at preventing stroke (SUCRA 82.63%). In conclusion, LAAO was associated with lower mortality compared with DOACs, and both LAAO and DOACs significantly reduce mortality compared with warfarin. Future trials are needed to rule out a significant inferiority of LAAO compared with DOACs in terms of stroke and bleeding risks.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • January CT
        • Wann LS
        • Calkins H
        • Chen LY
        • Cigarroa JE
        • Cleveland JC
        • Ellinor PT
        • Ezekowitz MD
        • Field ME
        • Furie KL
        • Heidenreich PA
        • Murray KT
        • Shea JB
        • Tracy CM
        • Yancy CW.
        2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
        J Am Coll Cardiol. 2019; 74: 104-132
        • Reddy VY
        • Sievert H
        • Halperin J
        • Doshi SK
        • Buchbinder M
        • Neuzil P
        • Huber K
        • Whisenant B
        • Kar S
        • Swarup V
        • Gordon N
        • Holmes D
        PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
        JAMA. 2014; 312: 1988-1998
        • Glikson M
        • Wolff R
        • Hindricks G
        • Mandrola J
        • Camm AJ
        • Lip GYH
        • Fauchier L
        • Betts TR
        • Lewalter T
        • Saw J
        • Tzikas A
        • Sternik L
        • Nietlispach F
        • Berti S
        • Sievert H
        • Bertog S
        • Meier B.
        EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update.
        EuroIntervention. 2020; 15: 1133-1180
        • Osmancik P
        • Herman D
        • Neuzil P
        • Hala P
        • Taborsky M
        • Kala P
        • Poloczek M
        • Stasek J
        • Haman L
        • Branny M
        • Chovancik J
        • Cervinka P
        • Holy J
        • Kovarnik T
        • Zemanek D
        • Havranek S
        • Vancura V
        • Peichl P
        • Tousek P
        • Lekesova V
        • Jarkovsky J
        • Novackova M
        • Benesova K
        • Widimsky P
        • Reddy VY
        PRAGUE-17 Trial Investigators. 4-year outcomes After left atrial appendage closure Versus nonwarfarin oral anticoagulation for atrial fibrillation.
        J Am Coll Cardiol. 2022; 79: 1-14
        • Holmes DR
        • Kar S
        • Price MJ
        • Whisenant B
        • Sievert H
        • Doshi SK
        • Huber K
        • Reddy VY.
        Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
        • Hutton B
        • Salanti G
        • Caldwell DM
        • Chaimani A
        • Schmid CH
        • Cameron C
        • Ioannidis JPA
        • Straus S
        • Thorlund K
        • Jansen JP
        • Mulrow C
        • Catalá-López F
        • Gøtzsche PC
        • Dickersin K
        • Boutron I
        • Altman DG
        • Moher D.
        The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.
        Ann Intern Med. 2015; 162: 777-784
        • Salanti G
        • Ades AE
        • Ioannidis JPA.
        Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.
        J Clin Epidemiol. 2011; 64: 163-171
      1. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, eds. Cochrane Handbook for Systematic Reviews of Interventions version 6.2; 2021. Cochrane. Available at: http://www.training.cochrane.org/handbook. Accessed on March 15, 2021.

        • R Core Team
        R: A Language and Environment for Statistical Computing.
        R Foundation for Statistical Computing, 2021 (Accessed on June 25, 2021)
        • Gelman A
        • Rubin DB.
        Inference from iterative simulation using multiple sequences.
        Stat Sci. 1992; 7: 457-472
        • Sterne JAC
        • Savović J
        • Page MJ
        • Elbers RG
        • Blencowe NS
        • Boutron I
        • Cates CJ
        • Cheng HY
        • Corbett MS
        • Eldridge SM
        • Emberson JR
        • Hernán MA
        • Hopewell S
        • Hróbjartsson A
        • Junqueira DR
        • Jüni P
        • Kirkham JJ
        • Lasserson T
        • Li T
        • McAleenan A
        • Reeves BC
        • Shepperd S
        • Shrier I
        • Stewart LA
        • Tilling K
        • White IR
        • Whiting PF
        • Higgins JPT.
        RoB 2: a revised tool for assessing risk of bias in randomised trials.
        BMJ. 2019; 366: l4898
        • Mieghem NM Van
        • Unverdorben M
        • Hengstenberg C
        • Möllmann H
        • Mehran R
        • López-Otero D
        • Nombela-Franco L
        • Moreno R
        • Nordbeck P
        • Thiele H
        • Lang I
        • Zamorano JL
        • Shawl F
        • Yamamoto M
        • Watanabe Y
        • Hayashida K
        • Hambrecht R
        • Meincke F
        • Vranckx P
        • Jin J
        • Boersma E
        • Rodés-Cabau J
        • Ohlmann P
        • Capranzano P
        • Kim HS
        • Pilgrim T
        • Anderson R
        • Baber U
        • Duggal A
        • Laeis P
        • Lanz H
        • Chen C
        • Valgimigli M
        • Veltkamp R
        • Saito S
        • Dangas GD
        • ENVISAGE-TAVI AF Investigators
        Edoxaban versus vitamin K Antagonist for atrial fibrillation after TAVR.
        N Engl J Med. 2021; 385: 2150-2160
        • Labovitz AJ
        • Rose DZ
        • Fradley MG
        • Meriwether JN
        • Renati S
        • Martin R
        • Kasprowicz T
        • Murtagh R
        • Kip K
        • Beckie TM
        • Stoddard M
        • Bozeman AC
        • McTigue T
        • Kirby B
        • Tran N
        • Burgin WS
        AREST Investigators Early apixaban use following stroke in patients with atrial fibrillation: results of the AREST trial.
        Stroke. 2021; 52: 1164-1171
        • Lakkireddy D
        • Thaler D
        • Ellis CR
        • Swarup V
        • Sondergaard L
        • Carroll J
        • Gold MR
        • Hermiller J
        • Diener HC
        • Schmidt B
        • MacDonald L
        • Mansour M
        • Maini B
        • O'Brien L
        • Windecker S
        Amplatzer Amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial.
        Circulation. 2021; 144: 1543-1552
        • Abdullaev S
        • Igamberdieva R
        • Sharapov O.
        MO123USE of rivaroxaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease*.
        Nephrol Dial Transplant. 2021; 36
        • De Vriese AS
        • Caluwé R
        • Van Der Meersch H
        • De Boeck K
        • De Bacquer D.
        Safety and Efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial.
        J Am Soc Nephrol. 2021; 32: 1474-1483
        • Galea R
        • De Marco F
        • Meneveau N
        • Aminian A
        • Anselme F
        • Gräni C
        • Huber AT
        • Teiger E
        • Iriart X
        • Babongo Bosombo F
        • Heg D
        • Franzone A
        • Vranckx P
        • Fischer U
        • Pedrazzini G
        • Bedogni F
        • Räber L
        • Valgimigli M
        Amulet or Watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial.
        Circulation. 2022; 145: 724-738
      2. ClinicalTrials.gov. A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with non-valvular atrial fibrillation in comparison to warfarin. Available at:https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjQn62A8db5AhVA1jgGHX5rCnkQFnoECAIQAQ&url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01136408&usg=AOvVaw0UKzJbk0ybWg5EUzyQI8cl. Accessed on June 10, 2021.

        • Reddy VY
        • Doshi SK
        • Kar S
        • Gibson DN
        • Price MJ
        • Huber K
        • Horton RP
        • Buchbinder M
        • Neuzil P
        • Gordon NT
        • Holmes DR
        PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials.
        J Am Coll Cardiol. 2017; 70: 2964-2975
        • Lecoffre C
        • De Peretti C
        • Gabet A
        • Grimaud O
        • Woimant F
        • Giroud M
        • Béjot Y
        • Olié V
        National trends in patients hospitalized for stroke and stroke mortality in France, 2008 to 2014.
        Stroke. 2017; 48: 2939-2945
        • Price MJ
        • Reddy VY
        • Valderrábano M
        • Halperin JL
        • Gibson DN
        • Gordon N
        • Huber KC
        • Holmes DR.
        Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience.
        JACC Cardiovasc Interv. 2015; 8: 1925-1932
        • Turagam MK
        • Osmancik P
        • Neuzil P
        • Dukkipati SR
        • Reddy VY.
        Left atrial appendage closure Versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials.
        J Am Coll Cardiol. 2020; 76: 2795-2797
        • Nielsen-Kudsk JE
        • Korsholm K
        • Damgaard D
        • Valentin JB
        • Diener HC
        • Camm AJ
        • Johnsen SP.
        Clinical outcomes associated With left atrial appendage occlusion Versus direct oral anticoagulation in atrial fibrillation.
        JACC Cardiovasc Interv. 2021; 14: 69-78
        • Li X
        • Wen SN
        • Li SN
        • Bai R
        • Liu N
        • Feng L
        • Ruan YF
        • Du X
        • Dong JZ
        • Ma CS.
        Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials and observational studies.
        Heart Rhythm. 2016; 13: 1203-1214
        • Koifman E
        • Lipinski MJ
        • Escarcega RO
        • Didier R
        • Kiramijyan S
        • Torguson R
        • Waksman R.
        Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: a network meta-analysis.
        Int J Cardiol. 2016; 205: 17-22
        • Banerjee A
        • Benedetto V
        • Gichuru P
        • Burnell J
        • Antoniou S
        • Schilling RJ
        • Strain WD
        • Ryan R
        • Watkins C
        • Marshall T
        • Sutton CJ.
        Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study.
        Heart. 2020; 106: 119-126
        • Ozaki AF
        • Choi AS
        • Le QT
        • Ko DT
        • Han JK
        • Park SS
        • Jackevicius CA.
        Real-world adherence and persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.
        Circ Cardiovasc Qual Outcomes. 2020; 13e005969
      3. Kapadia SR. SurPASS analysis, national cardiovascular data registry (NCDR) left atrial appendage occlusion (LAAO) registry-late-breaking trial session at the cardiovascular research technologies (CRT). Available at: https://www.watchman.com/en-us-implanter/clinical-evidence/surpass.html. Accessed on April 26, 2022.

        • López-López JA
        • Sterne JAC
        • Thom HHZ
        • Higgins JPT
        • Hingorani AD
        • Okoli GN
        • Davies PA
        • Bodalia PN
        • Bryden PA
        • Welton NJ
        • Hollingworth W
        • Caldwell DM
        • Savović J
        • Dias S
        • Salisbury C
        • Eaton D
        • Stephens-Boal A
        • Sofat R.
        Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis.
        BMJ. 2017; 359: j5058